Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma

PURPOSE: Chimeric antigen receptor (CAR) T-cell therapy of B-cell malignancies has proved to be effective. We show how the same approach of CAR T cells specific for CD30 (CD30.CAR-Ts) can be used to treat Hodgkin lymphoma (HL). METHODS: We conducted 2 parallel phase I/II studies (ClinicalTrials.gov...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Ramos, Carlos A., Grover, Natalie S., Beaven, Anne W., Lulla, Premal D., Wu, Meng-Fen, Ivanova, Anastasia, Wang, Tao, Shea, Thomas C., Rooney, Cliona M., Dittus, Christopher, Park, Steven I., Gee, Adrian P., Eldridge, Paul W., McKay, Kathryn L., Mehta, Birju, Cheng, Catherine J., Buchanan, Faith B., Grilley, Bambi J., Morrison, Kaitlin, Brenner, Malcolm K., Serody, Jonathan S., Dotti, Gianpietro, Heslop, Helen E., Savoldo, Barbara
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2020
Témata:
ORIGINAL REPORTS
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7655020/
https://ncbi.nlm.nih.gov/pubmed/32701411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01342
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky